Replies to post #58720 on Nutra Pharma Corp (NPHC)

[Knkn]

I trust him. It's your information I question because he's already addressed all these things. The India and China deals didn't come to fruition but I'm sure there are still opportunities there.

The value is the IP, not the sales but sales are increasing. Did you hear about the new equipment that can fill 40 bottles a minute. They are getting ready for big moves forward, that's why I continue to add here.

[cngreen]

Those are accusations, not proof at all.

Remember a couple of items already thrown out from SEC cause judge called BS. Thats a rarity for a jusde to dismiss claims. Also you can look up nphc sent product to india. Thats a FACT. More SEC BS. What else from the accusations are BS.


shorts beware. Deitsch has been coming thru all year with what he said he would. 2021 Accomplishments here.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166038487

he lied about contracts in India and China

[carolinatiger]

As you know Rik already answered this, but I will refresh your memory.

We never stated to have contracts in China. We received CPAM approval many years ago and started working with the Vancouver Commodities Group to identify potential distribution in China. We were never able to put together a deal that would have been beneficial to the company. We are continuing to work with other vendors and will announce any potential new distribution deals.

As for India, we had a contract with S. Zhaveri Pharmakem. They ordered a few times and we were able to legally sell the product in India through a homeopathic import license. The issue in that case was the company that acted as a middleman in the transaction. They primarily distribute American food products and condiments in India, but said that they could distribute our products as well. They started charging ridiculous management fees on the Indian side, which made our products too expensive for the market. We couldn't go around our contract with them at the time, so we halted the efforts in India until those contracts expired. We are now in talks with several new potential importers in India, but this process has been slow due to the COVID outbreak.

Now that we've been able to take back all of our products from outside vendors and distributors, we've been able to grow our online presence; expand our products into small-chain pharmacies and hospitals; and re-engage foreign distributors. Our goal this year is to roll into retail markets in the United States.

We'll be working on increasing revenues through product sales while we pursue our Multiple Sclerosis clinical platform and move our projects forward on Nerve Agent Countermeasures.


Rik